Ocular myasthenia gravis: a review and practical guide for clinicians

References

• Gilhus NE. Myasthenia gravis. N Engl J Med 2016; 375: 2570–2581.
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Verschuvren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015; 14: 1023–1036.
   PubMed Web of Science ®Google Scholar
• Howard JJ Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann NY Acad Sci 2018; 1412: 113–128.
   PubMed Web of Science ®Google Scholar
• Binks S, Vincent A, Palace J. Myasthenia gravis: a clinical-immunological update. J Neurol 2016; 263: 826–834.
   PubMed Web of Science ®Google Scholar
• Kondo K, Monden Y. Thymoma and myasthenia gravis: a clinical study of 1,089 patients from Japan. Ann Thorac Surg 2005; 79: 219–224.
   PubMed Web of Science ®Google Scholar
• Romi F, Gilhus NE, Varhaug JE, et al. Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study. Eur J Neurol 2003; 10: 701–706.
   PubMed Web of Science ®Google Scholar
• Nagia L, Lemos J, Abusamra K, et al. Prognosis of ocular myasthenia gravis: retrospective multicenter analysis. Ophthalmology 2015; 122: 1517–1521.
   Web of Science ®Google Scholar
• Hendricks TM, Bhatti MT, Hodge DO, et al. Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study. Am J Ophthalmol 2019; 205: 99–105.
   PubMed Web of Science ®Google Scholar
• Scherer K, Bedlack RS, Simel DL. Does this patient have myasthenia gravis? JAMA 2005; 293: 1906–1914.
   PubMed Web of Science ®Google Scholar
• Ahmad K, Wright M, Lueck CJ. Ptosis. Pract Neurol 2011; 11: 332–340.
   Google Scholar
• Cogan DG. Myasthenia gravis: a review of the disease and a description of lid twitch as a characteristic sign. Arch Ophthalmol 1965; 74: 217–221.
   PubMedGoogle Scholar
• Singman EL, Matta NS, Silbert DI. Use of the Cogan lid twitch to identify myasthenia gravis. J Neuro-Ophthalmol 2011; 31: 239–240.
   Web of Science ®Google Scholar
• Van Stavern GP, Bhatt A, Haviland J, et al. A prospective study assessing the utility of Cogan’s lid twitch sign in patients with isolated unilateral or bilateral ptosis. J Neurol Sci 2007; 256: 84–85.
   Web of Science ®Google Scholar
• Apinyawasisuk A, Zhou XMS, Tian JJ, et al. Validity of forced eyelid closure test: a novel clinical screening test for ocular myasthenia gravis. J Neuro-Ophthalmol 2017; 37: 253–257.
   Google Scholar
• Cleary M, Williams GJ, Metcalfe RA. The pattern of extra-ocular muscle involvement in ocular myasthenia. Strabismus 2008; 16: 11–18.
   PubMedGoogle Scholar
• Pike-Lee T, Hill J, Li J, et al. Comitant ocular deviation in myasthenia gravis. J Neuro-Ophthalmol 2020 Aug 28; Volume Publish Ahead of Print. DOI:https://doi.org/10.1097/WNO.0000000000001056
   Google Scholar
• Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Discord 2006; 16: 459–467.
   PubMed Web of Science ®Google Scholar
• O’Hare M, Doughty C. Update on ocular myasthenia gravis. Semin Neurol 2019; 39: 749–760.
   Web of Science ®Google Scholar
• Chatzistefanou KI, Kouris T, Iliakis E, et al. The ice pack test in the differential diagnosis of myasthenic diplopia. Ophthalmology 2009; 116: 2236–2243.
   PubMed Web of Science ®Google Scholar
• Peeler CE, De Lott LB, Nagia L, et al. Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis. JAMA Neurol 2015; 72: 1170–1174.
   PubMed Web of Science ®Google Scholar
• Chung IY, Sheth SJ, Wells KK, et al. The usefulness of anti-acetylcholine receptor binding antibody testing in diagnosing ocular myasthenia gravis. J Neuro-Ophthalmol 2020 Aug 28; Volume Publish Ahead of Print. DOI:https://doi.org/10.1097/WNO.0000000000001061
   Google Scholar
• Rousseff RT. Diagnosis of myasthenia gravis. J Clin Med 2021; 10: 1736.
   Web of Science ®Google Scholar
• Meriggioli MN, Sanders DB. Myasthenia gravis: diagnosis. Semin Neurol 2004; 24: 31–39.
   PubMed Web of Science ®Google Scholar
• Chaudhuri Z, Demer JL. Sagging eye syndrome: connective tissue involution as a cause of horizontal and vertical strabismus in older patients. JAMA Ophthalmol 2013; 131: 619–625.
   PubMed Web of Science ®Google Scholar
• Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2002; 73: 766–768.
   PubMed Web of Science ®Google Scholar
• Lonati D, Schicchi A, Crevani M, et al. Foodborne botulism: clinical diagnosis and medical treatment. Toxins (Basel) 2020; 12: 509.
   PubMed Web of Science ®Google Scholar
• Mori M, Kuwabara S, Fukutake T, et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001; 56: 1104–1106.
   PubMed Web of Science ®Google Scholar
• Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003; 60: 243–248.
   PubMedGoogle Scholar
• Mee J, Paine M, Byrne E, et al. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuro-Ophthalmol 2003; 23: 251–255.
   Web of Science ®Google Scholar
• Wong SH, Petrie A, Plant GT. Ocular myasthenia gravis: toward a risk of generalization score and sample size calculation for a randomized controlled trial of disease modification. J Neuro-Ophthalmol 2016; 36: 252–258.
   Web of Science ®Google Scholar
• Sabre L, Maddison P, Wong SH, et al. miR-30e-5p as predictor of generalization in ocular myasthenia gravis. Ann Clin Transl Neurol 2019; 6: 243–251.
   PubMed Web of Science ®Google Scholar
• Evoli A, Batocchi AP, Minisci C, et al. Therapeutic options in ocular myasthenia gravis. Neuromuscular Disord 2001; 11: 208–216.
   PubMed Web of Science ®Google Scholar
• Kerty E, Elsais A, Argov Z, et al. EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol 2014; 21: 687–693.
   PubMed Web of Science ®Google Scholar
• Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis – 2020 update. Neurology 2021; 96: 114–122.
   PubMed Web of Science ®Google Scholar
• Bruce BB, Kupersmith MJ. Safety of prednisone for ocular myasthenia gravis. J Neuro-Ophthalmol 2012; 32: 212–215.
   Web of Science ®Google Scholar
• Benatar M, McDermott MP, Sanders DB, et al.; for the Muscle Study Group (MSG). Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle Nerve 2016; 53: 363–369.
   PubMed Web of Science ®Google Scholar
• Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 2016; 375: 511–522.
   PubMed Web of Science ®Google Scholar